About AVT
Browse Articles
Customer Services

Original article

Inhibitory effects of lithium chloride on replication of type II porcine reproductive and respiratory syndrome virus in vitro

Jin Cui, Jiexiong Xie, Ming Gao, Han Zhou, Yao Chen, Tiantian Cui, Xiaolei Bai, Heng Wang, Guihong Zhang

Corresponding author name: Guihong Zhang
Corresponding author e-mail: guihongzh@scau.edu.cn

Citation: Antiviral Therapy 2015; 20:565-572
doi: 10.3851/IMP2924

Date accepted: 21 August 2014
Date published online: 05 January 2015


Background: Porcine reproductive and respiratory syndrome (PRRS) is one of the most serious diseases affecting the swine industry worldwide; however, there are no efficient control strategies against PRRS virus (PRRSV) at present. Therefore, development of new antiviral treatment strategies is urgently needed. As reported, lithium chloride (LiCl) can efficiently impair the replication of a variety of viruses, including infectious bronchitis coronavirus (IBV) and transmissible gastroenteritis coronavirus (TGEV). In this report, we explored whether LiCl had the potential to inhibit PRRSV infection.

Methods: MARC-145 cells were treated with LiCl at various stages of PRRSV life cycle. Virus titration assay was performed to determine the virus infectivity. The expression of viral mRNA and protein was measured by real-time PCR and indirect immunofluorescence assay, respectively. The transcript levels of cytokines were evaluated by real-time PCR.

Results: LiCl significantly suppressed the synthesis of viral RNA and protein; however, it did not block PRRSV binding and entry. Further studies confirmed that LiCl inhibited PRRSV replication at an early stage and TNF-α, an antiviral cytokine, was significantly increased after LiCl treatment. Thus, we suggested that LiCl inhibited PRRSV infection by up-regulating the level of antiviral cytokine TNF-α at an early infection stage.

Conclusions: Our findings imply that the LiCl has the potential to be used as anti-PRRSV therapy.


Copyright © 2021 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.